de Barclays Lexicon Pharmaceuticals LXRX Historial de posiciones en acciones
Compró
Mantenido
Vendió
| Trimestre | Valor de mercado | Estado | Núm. de acciones |
Cambio en la participación | Valor operado | Peso en el portafolio | Posición de la cartera | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | USD 930 k | Comprar |
387,483
+281,996
| +267% | +USD 549 k | ﹤0.01% | 2836 |
|
|
2026
Q1 | USD 165 k | Vender |
105,487
-89,256
| -46% | -USD 130 k | ﹤0.01% | 3805 |
|
|
2025
Q4 | USD 224 k | Comprar |
194,743
+162,881
| +511% | +USD 224 k | ﹤0.01% | 4255 |
|
|
2025
Q3 | USD 43 k | Vender |
31,862
-408
| -1% | -USD 463 | ﹤0.01% | 4802 |
|
|
2025
Q2 | USD 30.5 k | Vender |
32,270
-113,801
| -78% | -USD 73.7 k | ﹤0.01% | 4787 |
|
|
2025
Q1 | USD 67.3 k | Vender |
146,071
-97,245
| -40% | -USD 61.4 k | ﹤0.01% | 4528 |
|
|
2024
Q4 | USD 180 k | Comprar |
243,316
+49,443
| +26% | +USD 59.6 k | ﹤0.01% | 4363 |
|
|
2024
Q3 | USD 304 k | Comprar |
193,873
+154,436
| +392% | +USD 275 k | ﹤0.01% | 4081 |
|
|
2024
Q2 | USD 66.3 k | Vender |
39,437
-25,182
| -39% | -USD 45.2 k | ﹤0.01% | 4097 |
|
|
2024
Q1 | USD 155 k | Vender |
64,619
-62,397
| -49% | -USD 134 k | ﹤0.01% | 4238 |
|
|
2023
Q4 | USD 194 k | Comprar |
127,016
+87,827
| +224% | +USD 104 k | ﹤0.01% | 4433 |
|
|
2023
Q3 | USD 42.7 k | Comprar |
39,189
+1,520
| +4% | +USD 2.67 k | ﹤0.01% | 3937 |
|
|
2023
Q2 | USD 86.3 k | Vender |
37,669
-4,627
| -11% | -USD 12.3 k | ﹤0.01% | 3609 |
|
|
2023
Q1 | USD 103 k | Comprar |
42,296
+19,936
| +89% | +USD 45.7 k | ﹤0.01% | 4158 |
|
|
2022
Q4 | USD 42.7 k | Comprar |
22,360
+18,829
| +533% | +USD 40.1 k | ﹤0.01% | 4604 |
|
|
2022
Q3 | USD 8 k | Vender |
3,531
-71,723
| -95% | -USD 199 k | ﹤0.01% | 4392 |
|
|
2022
Q2 | USD 140 k | Vender |
75,254
-7,983
| -10% | -USD 15.2 k | ﹤0.01% | 3614 |
|
|
2022
Q1 | USD 175 k | Vender |
83,237
-1,733
| -2% | -USD 4.8 k | ﹤0.01% | 3501 |
|
|
2021
Q4 | USD 335 k | Comprar |
84,970
+57,223
| +206% | +USD 278 k | ﹤0.01% | 3373 |
|
|
2021
Q3 | USD 134 k | Comprar |
27,747
+14,497
| +109% | +USD 59.5 k | ﹤0.01% | 3788 |
|
|
2021
Q2 | USD 60 k | Vender |
13,250
-28,378
| -68% | -USD 137 k | ﹤0.01% | 4056 |
|
|
2021
Q1 | USD 244 k | Comprar |
41,628
+28,248
| +211% | +USD 196 k | ﹤0.01% | 3615 |
|
|
2020
Q4 | USD 46 k | Vender |
13,380
-5,779
| -30% | -USD 11 k | ﹤0.01% | 4441 |
|
|
2020
Q3 | USD 27 k | Vender |
19,159
-123,870
| -87% | -USD 221 k | ﹤0.01% | 4838 |
|
|
2020
Q2 | USD 287 k | Comprar |
143,029
+72,550
| +103% | +USD 142 k | ﹤0.01% | 3791 |
|
|
2020
Q1 | USD 138 k | Comprar |
70,479
+12,375
| +21% | +USD 36.8 k | ﹤0.01% | 4563 |
|
|
2019
Q4 | USD 241 k | Comprar |
58,104
+33,100
| +132% | +USD 127 k | ﹤0.01% | 4893 |
|
|
2019
Q3 | USD 75 k | Vender |
25,004
-2,050
| -8% | -USD 6.35 k | ﹤0.01% | 5691 |
|
|
2019
Q2 | USD 170 k | Comprar |
27,054
+10,944
| +68% | +USD 65.5 k | ﹤0.01% | 5262 |
|
|
2019
Q1 | USD 89 k | Comprar |
16,110
+13,503
| +518% | +USD 82 k | ﹤0.01% | 5451 |
|
|
2018
Q4 | USD 18 k | Vender |
2,607
-20,042
| -88% | -USD 162 k | ﹤0.01% | 5955 |
|
|
2018
Q3 | USD 241 k | Comprar |
22,649
+19,485
| +616% | +USD 223 k | ﹤0.01% | 4858 |
|
|
2018
Q2 | USD 38 k | Vender |
3,164
-15,800
| -83% | -USD 162 k | ﹤0.01% | 5807 |
|
|
2018
Q1 | USD 163 k | Vender |
18,964
-39,281
| -67% | -USD 363 k | ﹤0.01% | 4999 |
|
|
2017
Q4 | USD 575 k | Comprar |
58,245
+19,874
| +52% | +USD 206 k | ﹤0.01% | 3665 |
|
|
2017
Q3 | USD 471 k | Comprar |
38,371
+8,123
| +27% | +USD 120 k | ﹤0.01% | 3692 |
|
|
2017
Q2 | USD 498 k | Comprar |
30,248
+17,518
| +138% | +USD 271 k | ﹤0.01% | 3532 |
|
|
2017
Q1 | USD 183 k | Vender |
12,730
-18,084
| -59% | -USD 268 k | ﹤0.01% | 4414 |
|
|
2016
Q4 | USD 426 k | Comprar |
30,814
+27,223
| +758% | +USD 437 k | ﹤0.01% | 3513 |
|
|
2016
Q3 | USD 64 k | Vender |
3,591
-59,625
| -94% | -USD 960 k | ﹤0.01% | 4832 |
|
|
2016
Q2 | USD 907 k | Comprar |
63,216
+60,159
| +1,968% | +USD 816 k | ﹤0.01% | 2702 |
|
|
2016
Q1 | USD 34 k | Vender |
3,057
-32,929
| -92% | -USD 345 k | ﹤0.01% | 4982 |
|
|
2015
Q4 | USD 468 k | Comprar |
35,986
+5,885
| +20% | +USD 72.4 k | ﹤0.01% | 3272 |
|
|
2015
Q3 | USD 300 k | Comprar |
30,101
+29,304
| +3,677% | +USD 320 k | ﹤0.01% | 3800 |
|
|
2015
Q2 | USD 6 k | Vender |
797
-4,130
| -84% | -USD 30.3 k | ﹤0.01% | 6355 |
|
|
2015
Q1 | USD 0 | Vender |
4,927
-1,895
| -28% | -USD 12.9 k | ﹤0.01% | 7174 |
|
|
2014
Q4 | USD 0 | Vender |
6,822
-2,288
| -25% | -USD 18.4 k | ﹤0.01% | 7460 |
|
|
2014
Q3 | USD 63 k | Vender |
9,110
-8,717
| -49% | -USD 93.1 k | ﹤0.01% | 5683 |
|
|
2014
Q2 | USD 125 k | Comprar |
17,827
+6,890
| +63% | +USD 74 k | ﹤0.01% | 5247 |
|
|
2014
Q1 | USD 77 k | Comprar |
10,937
+8,615
| +371% | +USD 110 k | ﹤0.01% | 5659 |
|
|
2013
Q4 | USD 16 k | Vender |
2,322
-264
| -10% | -USD 4.2 k | ﹤0.01% | 6821 |
|
|
2013
Q3 | USD 36 k | Vender |
2,586
-119
| -4% | -USD 2 k | ﹤0.01% | 6240 |
|
|
2013
Q2 | USD 41 k | Comprar |
+2,705
| Nuevas | +USD 41.1 k | ﹤0.01% | 6440 |
|
Otros fondos que tienen LXRX en su cartera
AG
SL
Posición de Barclays en LXRX: resumen de T2 2026
Barclays aumentó su participación en Lexicon Pharmaceuticals (LXRX) en 267% durante T2 2026, al comprar aproximadamente USD 549 k y elevar la posición a 387,483 acciones con un valor de USD 930 k. La posición representa ﹤0.01% de la cartera y ocupa el puesto #2836.
Barclays reportó por primera vez una posición en LXRX en T2 2013 y la ha mantenido durante 53 trimestres desde entonces. Al cierre de T2 2026, 149 fondos que sigue Wall St. Rank mantienen una posición en LXRX.
- Al cierre de T2 2026, Barclays tenía 387,483 acciones de Lexicon Pharmaceuticals con un valor de USD 930 k.
- Barclays compró 281,996 acciones de Lexicon Pharmaceuticals en T2 2026, por un monto estimado de USD 549 k.
- Lexicon Pharmaceuticals representó ﹤0.01% de la cartera de Barclays en T2 2026 y fue su posición número 2836.
- Barclays reportó por primera vez una posición en Lexicon Pharmaceuticals en T2 2013 y la ha mantenido durante 53 trimestres desde entonces.
- Al cierre de T2 2026, 149 fondos que sigue Wall St. Rank tenían Lexicon Pharmaceuticals en cartera.
Según el Informe 13F de Barclays correspondiente a T2 2026, presentado el 14 ago 2026.